Is Sanofi Planning High-Level Changes At India's Vaccines Unit Shantha? A Leading Biocon Scientist Joins Shantha
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Two years after it bagged Indian vaccines specialist Shantha Biotechnics Ltd. with an aim to develop low-cost vaccines, Sanofi is set to rollout significant changes in the management of its acquired Hyderabad site in Central India